Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15354078 | 0.87 | CHRNB2 (0.35) | CHRNB2CHRNB4CHRNA4CHRNA3 | |
| SCHEMBL23902111 | 0.81 | ALDH1A1 (0.33) | CHRNB2CHRNB4CHRNA4CHRNA3 | |
| SCHEMBL12766249 | 0.81 | ALDH1A1 (0.33) | CHRNB2CHRNB4CHRNA4CHRNA3 | |
| SCHEMBL23564628 | 0.81 | ALDH1A1 (0.33) | CHRNB2CHRNB4CHRNA4CHRNA3 | |
| SCHEMBL19982694 | 0.75 | CHRNB2 (0.30) | CHRNB2CHRNB4CHRNA4CHRNA3 | |
| SCHEMBL13701610 | 0.75 | CHRNB2 (0.30) | CHRNB2CHRNB4CHRNA4CHRNA3 | |
| SCHEMBL18900262 | 0.73 | — | — | |
| SCHEMBL19397684 | 0.73 | — | — | |
| SCHEMBL438504 | 0.73 | — | — | |
| SCHEMBL24209106 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11382979-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220175930-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2022-06-09 | — | — | US | disclosed |
| US-20220175929-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175929-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | CHRNB2 4172/4885CHRNB4 4143/4885CHRNA4 4242/4885 |
| US-11382979-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | CHRNB2 4172/4885CHRNB4 4143/4885CHRNA4 4242/4885 |
| US-20220175930-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | CHRNB2 4172/4885CHRNB4 4143/4885CHRNA4 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.